<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ASAP Discovery Outputs on ASAP Discovery Consortium</title><link>https://asapdiscovery.org/outputs/</link><description>Recent content in ASAP Discovery Outputs on ASAP Discovery Consortium</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><atom:link href="https://asapdiscovery.org/outputs/index.xml" rel="self" type="application/rss+xml"/><item><title>Viral Families</title><link>https://asapdiscovery.org/outputs/viral-families/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/viral-families/</guid><description>ASAP aims to discover direct-acting antivirals with broad antiviral activity within a viral family, but the difficulty of achieving this goal means that some of our program objectives are more narrowly focused on viral family members of greatest pandemic concern.
coronaviridae Coronavirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
flaviviridae Flavivirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.</description></item><item><title>Targeting Opportunities</title><link>https://asapdiscovery.org/outputs/targeting-opportunities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/targeting-opportunities/</guid><description>A targeting opportunity provides an overview of the opportunity for targeting new antivirals to a specific target protein and mode of action. This overview is intended to summarize relevant information for drug hunters, including the relevant domain and binding sites to target, notable chemical matter, rationale for antiviral effects, and other useful information in prosecuting a discovery compaign aginst the target.
SARS-CoV-2 / MERS-CoV Mpro protease Targeting Opportunity for SARS-CoV-2 / MERS-CoV Mpro protease [2023-03-19] Initial draft</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2 / MERS-CoV Mpro protease SARS-CoV-2/MERS-CoV Mpro lead optimization biochemical assay - negative data
[assay data] [metadata] This data release contains assay data for compounds ASAP is not pursuing toward nomination of a development candidate as part of this discovery program. Dengue NS2B-NS3 protease DENV-2 NS2B-NS3 protease covalent fragment screen and hit confirmation assay data
[assay data] [metadata] Biochemical assay data for single-concentration fragment screen and follow-up multi-point titration for hits.</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>SARS-CoV-2 / MERS-CoV Mpro Fragalysis interactive exploration of X-ray fragment screen of SARS-CoV-2 Mpro xray-fragment-screen [ 2020-03-18 ] Contributing Projects and Cores: Project 2 Structural Biology Core We performed an exhaustive crystallographic fragment screen to probe the Mpro active site, and to identify opportunities for fragment merging or growing. Additionally, a library of mild electrophilic fragments was screened by mass spectrometry for probing the binding properties around the active site cysteine.</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description>ASAP aims to publish preprints to ensure our scientific advances are rapidly and openly available.</description></item><item><title>Mutation Data</title><link>https://asapdiscovery.org/outputs/mutation-data/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/mutation-data/</guid><description> Coronavirus MERS-CoV/SARS-CoV-2 Mpro Coronavirus nsp3-mac1 Item 3</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description>A Target Product Profile (TPP) describes the desired characteristics of a drug product aimed to treat a particular disease or set of diseases.
All ASAP TPPs are draft TPPs intended to help guide the development of target candidate profiles (TCPs) for antiviral discovery within the ASAP Discovery Consortium. ASAP works with stakeholders around the globe (such as the World Health Organization) to align TPPs to ensure they meet the needs of communities and fulfill our mission of global, equitable, and affordable access to antiviral therapies.</description></item><item><title>Target Enabling Packages (TEPs)</title><link>https://asapdiscovery.org/outputs/target-enabling-packages/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-enabling-packages/</guid><description>A Target Enabling Package (TEP) is a complete data package needed to enable structure-based drug discovery against an antiviral target. Pioneered by the Structural Genomics Consortium, each TEP contains relevant protein constructs and plasmid resources for one or more viral family members, protein expression and purification protocols, crystallization conditions, structures from an X-ray fragment screen at the Diamond Light Source XChem facility, small molecule hits, and biochemical assay protocols with at least one validated inhibitor with quantifiable activity.</description></item><item><title>Assay Cascades</title><link>https://asapdiscovery.org/outputs/assay-cascades/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-cascades/</guid><description>An assay cascade is a defined set of assays and progression criteria used by a drug discovery program to achieve its Target Candidate Profile (TCP) goals in a time- and cost-effective manner.
SARS-CoV-2 Mpro assay cascade from the COVID Moonshot SARS-CoV-2 Mpro assay cascade from the COVID Moonshot SARS-CoV-2 / MERS-CoV Mpro assay cascade SARS-CoV-2 / MERS-CoV Mpro assay cascade [2022-06-01] Initial draft SARS-CoV nsp3 Mac1 assay cascade for lead nomination SARS-CoV nsp3 Mac1 assay cascade for lead nomination draft [2022-06-01] Initial draft</description></item><item><title>Assay Protocols</title><link>https://asapdiscovery.org/outputs/assay-protocols/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-protocols/</guid><description>MERS-CoV Main Protease (Mpro) Fluorescence Dose Response This is a functional, biochemical assay used to identify treatments for viral infectious disease in MERS 3C-like main viral protease. Utilizing a direct enzyme activity measurement method, the experiment was performed in a 384-well plate reading the fluorescence intensity. This assay tested the mode of action of inhibition.
protocols.io
SARS-CoV-2 Main Protease (Mpro) Fluorescence Dose Response This is a functional, biochemical assay used to identify treatments for viral infectious disease that target SARS-CoV-2 3C-like main viral protease (MPro).</description></item><item><title>Target Candidate Profiles (TCPs)</title><link>https://asapdiscovery.org/outputs/target-candidate-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-candidate-profiles/</guid><description>A Target Candidate Profile (TCP) describes the objectives an ASAP drug discovery program aims to achieve to produce a preclinical candidate. Our TCPs are informed by the corresponding Target Product Profiles (TPPs) for the corresponding disease.
MERS-CoV and SARS-CoV-2 Oral MPro protease inhibitor Targent Candidate Profile for MERS-CoV and SARS-CoV-2 Oral MPro protease inhibitor [2023-03-01] Initial draft SARS-CoV-2 Oral MPro protease inhibitor Targent Candidate Profile for SARS-CoV-2 Oral MPro protease inhibitor [2020-04-01] Initial draft SARS-CoV-2 Oral nsp3 Mac1 macrodomain inhibitor Targent Candidate Profile for SARS-CoV-2 Oral nsp3 Mac1 macrodomain inhibitor [2023-03-01] Initial draft</description></item><item><title>Covalent targeting</title><link>https://asapdiscovery.org/outputs/covalent-targeting/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/covalent-targeting/</guid><description>Dengue NS2B-NS3 protease DENV-2 NS2B-NS3 protease covalent fragment screen and hit confirmation assay data
[assay data] [metadata] Biochemical assay data for single-concentration fragment screen and follow-up multi-point titration for hits. West Nile NS2B-NS3 protease WNV NS2B-NS3 protease covalent fragment screen and hit confirmation assay data
[assay data] [metadata] Biochemical assay data for single-concentration fragment screen and follow-up multi-point titration for hits. Zika NS2B-NS3 protease ZIKV NS2B-NS3 protease covalent fragment screen and hit confirmation assay data</description></item><item><title>Preclinical program</title><link>https://asapdiscovery.org/outputs/preclinical/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/preclinical/</guid><description>SARS-CoV-2 Mpro</description></item><item><title>Investigational New Drug (IND) filings</title><link>https://asapdiscovery.org/outputs/investigational-new-drugs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/investigational-new-drugs/</guid><description>Program 1 Program 2</description></item><item><title>Clinical trials</title><link>https://asapdiscovery.org/outputs/clinical-trials/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/clinical-trials/</guid><description>ASAP does not currently have any programs that have reached clinical trials.</description></item><item><title>New Drug Approvals</title><link>https://asapdiscovery.org/outputs/new-drug-approvals/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/new-drug-approvals/</guid><description>ASAP does not currently have any programs that have reached New Drug Approval (NDA) status.</description></item><item><title/><link>https://asapdiscovery.org/outputs/img/icons/readme/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/img/icons/readme/</guid><description>Icons from The Noun Project Icons are CC-BY from The Noun Project
Credits (for CC-BY acknowledgments) assay-cascade.png : noun-chemistry-2954755 : Chemistry by Icon Factory from Noun Project clinical-trails.png : noun-medical-1053629 : medical by Raymond from Noun Project data.png : noun-save-5021426 : Save by Cetha Studio from Noun Project disease.png : noun-medical-3923610 : medical by Royyan Wijaya from Noun Project DMS.png : noun-mutation-4374976 : mutation by Adrien Coquet from Noun Project hit-to-lead.</description></item></channel></rss>